- AU$47.27m
- AU$42.83m
- AU$32.33m
Brief: Cyclopharm Ltd Says Advises Co And Unit Reached Settlement With Landauer Australia, Individual
Brief: Cyclopharm Posts 1H Revenue A$15.3 Million, Up 39% On PCP
Brief: Cyclopharm Says Inspection Of Kingsgrove By US FDA Will Be Conducted Between July Through Aug
Brief: Cyclopharm Says U.S. FDA Formally Acknowledged Receipt Of Co's 30 March 2023 Reply
Brief: Cyclopharm Says Co Has Acquired Dupharma Aps, Based In Copenhagen, Denmark
Brief: Cyclopharm Says FDA Approval For Technegas Expected Late 2023
Australia's Cyclopharm jumps on final review for FDA nod on medical device
Brief: Cyclopharm Says Sales Of Technegas In U.S. Expected To Commence In Late 2023
Brief: Cyclopharm Resolves To Pay Final Unfranked Dividend Of 0.5 AU Cents Per Share
Australia's Cyclopharm marks best day in a month on upbeat HY results
Cyclopharm rises on revenue outlook, U.S. FDA nod progress
Brief: Cyclopharm Says Expects 1H FY 2022 Total Unaudited Group Sales Revenue To Be About A$11.3 Mln
Australia's Cyclopharm rises as product shows COVID management potential
Brief: Cyclopharm Says Technegas Shown To Have Key Role In COVID-19 Diagnosis & Management
Australia Stock Exchange release from CYCLOPHARM : Date of Annual General Meeting
Australia Stock Exchange release from CYCLOPHARM : Change of Director's Interest Notice
Australia Stock Exchange release from CYCLOPHARM : S&P DJI Announces March 2022 Quarterly Rebalance
Australia Stock Exchange release from CYCLOPHARM : PRE_NR Ends: 17:13:11
Brief: Cyclopharm Posts FY Sales Revenue Of A$17.70 Million